Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech 2013 Revenues Inch up 2 Percent

NEW YORK (GenomeWeb News) – Life Technologies' full-year 2013 revenues increased 2 percent year over year, Thermo Fisher Scientific said today in a document filed with the US Securities and Exchange Commission.

Life Tech posted $3.87 billion in revenues, up from $3.80 billion in 2012. Its net income increased to $470.4 million from $430.4 million, Thermo Fisher said. It did not report Life Tech's EPS figure.

Life Tech's R&D costs rose 3 percent year over year to $352.8 million in 2013 from $341.9 million in 2012, and its SG&A costs increased about 10 percent to $1.15 billion from $1.05 billion.

Life Tech ended 2013 with $629.8 million in cash and cash equivalents.

Thermo Fisher completed its acquisition of Life Tech in February for about $13.6 billion plus the assumption of $1.5 billion in net debt. In January Thermo Fisher reported that its revenues for 2013 increased 5 percent year over year to $13.09 billion.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.